Bio-Techne Corp at Barclays Global Healthcare Conference Transcript
Hi. This is Jack Meehan with the Barclays Life Science Tools and Diagnostics team. Thank you for joining us this morning for the Barclays Virtual Health Care Conference. Pleased to be joined with -- now with Bio-Techne CEO, Chuck Kummeth as well as Head of Investor Relations, Dave Clair. Chuck, would you like to kick it off with any introductory comments?
Yes, thanks. I'll give a minute or 2 on just accompanying some background. So I've been here 7 years; most of my team, 5 or 6; brought in from places like Thermo Fisher and the places I've worked and as well as other areas like LifeTech, some strong team. Most of the people running our businesses have run billion-dollar things or bigger. So a great team going there.
We've done 15 acquisitions in the last 6 years, and we've grown from roughly about a $300 million revenue rate. When I started to -- we were 7 -- $14 million last fiscal year; June
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
